MOLECULAR DIAGNOSTICS CANCER MARKET ANALYSIS BY TYPE, APPLICATION, REGIONS AND COMPANIES FORECAST
2024-11-27 | Pages: 200+ | Report ID: BYR-26261 | Pharmaceuticals and Healthcare
Historical data: 2017 - 2023
Forecast period: 2025 - 2031
Quantitative units: Revenue in USD million and CAGR from 2025 to 2031
Report coverage: Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Molecular Diagnostics Cancer Market
1.1 SCOPE OF THE REPORT
1.2 MARKET SEGMENT ANALYSIS
1.3 REGULATORY SCENARIO BY REGION/COUNTRY
1.4 MARKET INVESTMENT SCENARIO STRATEGIC
1.5 MARKET ANALYSIS BY TYPE (USD MILLION)
1.6 MARKET ANALYSIS BY APPLICATION (USD MILLION)
2.1 DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS
2.1.1 MARKET DRIVER ANALYSIS
2.1.2 MARKET RESTRAINT ANALYSIS
2.1.3 MARKET OPPORTUNITY
2.1.4 MARKET CHALLENGES
3.1 INDUSTRY TRENDS
3.1.1 SWOT ANALYSIS
3.1.2 PESTEL ANALYSIS
3.1.3 PORTER’S FIVE FORCES ANALYSIS
3.2 POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS
4.1 COVID-19 ANALYSIS
5.1 GLOBAL MOLECULAR DIAGNOSTICS CANCER MARKET, SALES AREA, TYPE
5.2 MERGERS & ACQUISITIONS, PARTNERSHIPS, PRODUCT LAUNCH, AND COLLABORATION IN GLOBAL MOLECULAR DIAGNOSTICS CANCER MARKET
7.1 GLOBAL MOLECULAR DIAGNOSTICS CANCER MARKET SIZE AND SHARE (2017 - 2031) (USD MILLION)
8.1 GLOBAL MOLECULAR DIAGNOSTICS CANCER MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
8.2 GLOBAL MOLECULAR DIAGNOSTICS CANCER MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
9.1 GLOBAL MOLECULAR DIAGNOSTICS CANCER MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
9.2 GLOBAL MOLECULAR DIAGNOSTICS CANCER MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)
10.1 GLOBAL MOLECULAR DIAGNOSTICS CANCER MARKET SIZE AND SHARE BY REGION (2017 - 2023) (USD MILLION)
10.2 GLOBAL MOLECULAR DIAGNOSTICS CANCER MARKET SIZE AND SHARE BY REGION (2025 - 2031) (USD MILLION)
11.1 NORTH AMERICA MOLECULAR DIAGNOSTICS CANCER MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)
11.2 NORTH AMERICA MOLECULAR DIAGNOSTICS CANCER MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)
11.3 NORTH AMERICA MOLECULAR DIAGNOSTICS CANCER MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
11.4 NORTH AMERICA MOLECULAR DIAGNOSTICS CANCER MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
11.5 NORTH AMERICA MOLECULAR DIAGNOSTICS CANCER MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
11.6 NORTH AMERICA MOLECULAR DIAGNOSTICS CANCER MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)
12.1 EUROPE MOLECULAR DIAGNOSTICS CANCER MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)
12.2 EUROPE MOLECULAR DIAGNOSTICS CANCER MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)
12.3 EUROPE MOLECULAR DIAGNOSTICS CANCER MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
12.4 EUROPE MOLECULAR DIAGNOSTICS CANCER MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
12.5 EUROPE MOLECULAR DIAGNOSTICS CANCER MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
12.6 EUROPE MOLECULAR DIAGNOSTICS CANCER MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)
13.1 ASIA PACIFIC MOLECULAR DIAGNOSTICS CANCER MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)
13.2 ASIA PACIFIC MOLECULAR DIAGNOSTICS CANCER MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)
13.3 ASIA PACIFIC MOLECULAR DIAGNOSTICS CANCER MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
13.4 ASIA PACIFIC MOLECULAR DIAGNOSTICS CANCER MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
13.5 ASIA PACIFIC MOLECULAR DIAGNOSTICS CANCER MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
13.6 ASIA PACIFIC MOLECULAR DIAGNOSTICS CANCER MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)
14.1 LATIN AMERICA MOLECULAR DIAGNOSTICS CANCER MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)/p>
14.2 LATIN AMERICA MOLECULAR DIAGNOSTICS CANCER MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)
14.3 LATIN AMERICA MOLECULAR DIAGNOSTICS CANCER MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
14.4 LATIN AMERICA MOLECULAR DIAGNOSTICS CANCER MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
14.5 LATIN AMERICA MOLECULAR DIAGNOSTICS CANCER MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
14.6 LATIN AMERICA MOLECULAR DIAGNOSTICS CANCER MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)
15.1 MIDDLE EAST & AFRICA MOLECULAR DIAGNOSTICS CANCER MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)
15.2 MIDDLE EAST & AFRICA MOLECULAR DIAGNOSTICS CANCER MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)
15.3 MIDDLE EAST & AFRICA MOLECULAR DIAGNOSTICS CANCER MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
15.4 MIDDLE EAST & AFRICA MOLECULAR DIAGNOSTICS CANCER MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
15.5 MIDDLE EAST & AFRICA MOLECULAR DIAGNOSTICS CANCER MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
15.6 MIDDLE EAST & AFRICA MOLECULAR DIAGNOSTICS CANCER MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031)< (USD MILLION)/p>
16.1 Roche
16.1.1 COMPANY DETAILS
16.1.2 FINANCIALS (USD MILLION)
16.1.3 PRODUCT SUMMARY
16.1.4 RECENT DEVELOPMENTS
16.2 Danaher
16.3 Siemens
16.4 Abbott Laboratories
16.5 ICON Plc
16.6 AstraZeneca
16.7 MDxHealth
16.8 Invitae
16.9 PlexBio
16.10 Thermo Fisher Scientific
16.11 Guardant Health
16.12 Biocartis
16.13 Bio-Techne
16.14 Merck
16.15 Foundation Medicine
16.16 10X Genomics
16.17 Biodesix
16.18 CytoTrack
16.19 GenomOncology
16.20 Luminex
18.1 METHODOLOGY
18.2 RESEARCH DATA SOURCE
18.2.1 SECONDARY DATA
18.2.2 KEY DATA FROM SECONDARY
18.2.3 PRIMARY DATA
18.2.4 KEY DATA FROM PRIMARY
18.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS
18.2.6 MARKET ESTIMATION
18.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH
18.2.8 LEGAL DISCLAIMER
Market Segments
By TypePharmacogenomic Diagnosis
Liquid Biopsy
By Application
Respiratory Cancer
Cancer of Digestive System
Cancer of Urinary System
Cancer of Circulatory System
Motor System Cancer
Reproductive System Cancer
Companies
Roche
Danaher
Siemens
Abbott Laboratories
ICON Plc
AstraZeneca
MDxHealth
Invitae
PlexBio
Thermo Fisher Scientific
Guardant Health
Biocartis
Bio-Techne
Merck
Foundation Medicine
10X Genomics
Biodesix
CytoTrack
GenomOncology
Luminex
BROWSE INDUSTRY
- PROACTIVE
- QUALITY & RELIABILITY
- GLOBAL OUTREACH
- COMPETITIVE PRICING
WHY CHOOSE US
We manage our resources 24/7 to identify issues and address them before they become problems.
We are committed to providing reliable and highly accurate data with an excellent quality control system.
6 Major regions and 40+ countries level analysis accomplished.
Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery.